Medizone Intl. (fka MZEIQ)

[mtsr]

AsepticSure®


Progress Update


June 1, 2015



Medizone International appears on the cusp of strong commercial breakthroughs. The superior efficacy of the AsepticSure process backed by its unassailable science is no longer in question. AsepticSure has proven to be the only hospital disinfection, cleaning technology that repeatedly eliminates all known pathogens in the space treated, demonstrating in-hospital the ability to break the hospital acquired infection (HAI) reinfection cycle. At the provincial level in Canada the medical community is starting to take serious notice.



New Canadian Initiatives:



A Provincial Ministry of Health in Canada has recently requested a demonstration of AsepticSure at two of its major hospitals in two different cities. It should be noted that these are not trials, but demonstrations of the systems operation. Dr. Shannon, along with our Canadian distributor Wood-Wyant, will be conducting these demonstrations. It has been communicated to Dr. Shannon from this Provincial Ministry of Health's office that, "their search for a hospital disinfection technology suitable for adoption by the Province had been narrowed down to only one, AsepticSure."



This is understandable in that recent peer-reviewed scientific literature has made it abundantly clear that the claims made for the disinfection capabilities of the ultra violet light systems have been grossly overstated. Straight hydrogen peroxide technologies have proven far more time consuming, toxic to the environment, and far less efficacious. Only AsepticSure has continued to demonstrate its 6-log efficacy while fitting nicely into normal hospital workflows. It is absolutely "green" in the sense that all medical equipment remains in the room during cleaning and the 100% disinfected space is then available for immediate occupancy the moment the door is opened following the disinfection cycle.



The Provincial Ministry's purchasing agent is now playing a leading role in setting up these demonstrations, which are expected to take place in July following the Canadian National Infection Prevention and Control Conference in Victoria, BC. (This medical conference takes place June 14th through June 17, 2015.) At the conference, Queen's University Professor Dr. Dick Zoutman, will be giving two talks and poster presentations on AsepticSure's applications. These will be titled respectively, "Time, Cost Efficiency and Effectiveness of a Novel ozone-Hydrogen Peroxide Disinfection System (ARDS) During a Clostridium difficile Outbreak on an Acute Medical Unit" and "High Level Disinfection Effectiveness of a Novel Ozone-Hydrogen Peroxide Vapour Automated Room Disinfection System (ARDS) Against Non-Enveloped and Enveloped Viruses."



Activities in Preparation for US Market Entry:



Preliminary planning has recently been initiated for demonstration of efficacy trials at two US hospitals. The intent of these trials is to replicate what has been achieved at Quinte Health Care's Bellville General and Trenton Memorial Hospitals, breaking the isolation room re-infection cycle and stopping new HAI's in their tracks. These trials will be conducted by a leading hospital contract cleaning service company working with the hospitals quality assurance personnel.





Assuming a successful trial outcome with results unequivocally demonstrating a greater than 6-log (>99.9999%) disinfection capability in all critical spaces (which essentially resets infection prone problem rooms as the safest rooms in the hospital), adoption of AsepticSure as their technology of choice is a distinct possibility. Until start dates are established and announced by the contractor, we will not be releasing any additional information.


This update may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


For press information on Medizone International, please contact:
John Pentony, Investor Relations
T: [phone]
E:[e-mail]

Gary Hanauer, Media Contact
T: [phone]
E:[e-mail]

For more information, visit: http://www.medizoneint.com
Email: [e-mail]